Literature DB >> 18840076

Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes.

Timothy K Blackmore1, Laurens Manning, William J Taylor, Robert S Wallis.   

Abstract

Paradoxical reactions are immune-mediated exacerbations of disease triggered by tuberculosis treatment. Paradoxical reactions involving the central nervous system may be life threatening. Infliximab (tumor necrosis factor antibody) profoundly inhibits cellular immune responses to Mycobacterium tuberculosis. We describe a case in which infliximab was used to control steroid-resistant tuberculosis paradoxical reaction involving the central nervous system.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18840076     DOI： 10.1086/592695

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  49 in total

1.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

Review 2.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

3.  A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS.

Authors:  Denise C Hsu; Kimberly F Faldetta; Luxin Pei; Virginia Sheikh; Netanya S Utay; Gregg Roby; Adam Rupert; Anthony S Fauci; Irini Sereti
Journal:  Clin Infect Dis       Date:  2015-09-22       Impact factor: 9.079

4.  Pathogenesis and immune response in tuberculous meningitis.

Authors:  Bini Estela Isabel; Hernández Pando Rogelio
Journal:  Malays J Med Sci       Date:  2014-01

5.  The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans.

Authors:  David M Tobin; Jay C Vary; John P Ray; Gregory S Walsh; Sarah J Dunstan; Nguyen D Bang; Deanna A Hagge; Saraswoti Khadge; Mary-Claire King; Thomas R Hawn; Cecilia B Moens; Lalita Ramakrishnan
Journal:  Cell       Date:  2010-03-05       Impact factor: 41.582

6.  PPE38 modulates the innate immune response and is required for Mycobacterium marinum virulence.

Authors:  Dandan Dong; Decheng Wang; Ming Li; Hui Wang; Jia Yu; Chuan Wang; Jun Liu; Qian Gao
Journal:  Infect Immun       Date:  2011-10-28       Impact factor: 3.441

7.  Tuberculosis complicated by immune reconstitution inflammatory syndrome in a patient on anti-TNFα therapy for Crohn's disease.

Authors:  Caroline O'Dowd; Peter Kewin; John Morris; Mark Cotton
Journal:  BMJ Case Rep       Date:  2011-03-08

8.  Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent.

Authors:  Steffen Hess; Toni Hospach; Robert Nossal; Günther Dannecker; Klaus Magdorf; Frank Uhlemann
Journal:  Eur J Pediatr       Date:  2011-05-31       Impact factor: 3.183

Review 9.  Advancing host-directed therapy for tuberculosis.

Authors:  Robert S Wallis; Richard Hafner
Journal:  Nat Rev Immunol       Date:  2015-03-13       Impact factor: 53.106

Review 10.  Novel adjunctive therapies for the treatment of tuberculosis.

Authors:  A A Ordonez; M Maiga; S Gupta; E A Weinstein; W R Bishai; S K Jain
Journal:  Curr Mol Med       Date:  2014-03       Impact factor: 2.222
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.